The Carlyle Group Agrees to Acquire Johnson & Johnson#39;s Ortho-Clinical Diagnostics Business - - BioPharm International

ADVERTISEMENT

The Carlyle Group Agrees to Acquire Johnson & Johnson#39;s Ortho-Clinical Diagnostics Business


Global alternative asset manager The Carlyle Group, has agreed to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring, and confirming diseases, for $4.15 billion. The transaction is subject to customary regulatory approvals and is expected to close in the middle of 2014.

 “Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation,” said Stephen H. Wise, managing director of The Carlyle Group, in the press release. “Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide. We have been focused on the diagnostics industry for many years given its attractive growth prospects, driven by the crucial role it plays in health care decision-making and influencing patient outcomes. We believe that OCD, with its world-class employee base and talented management team, is poised for the next level of success.”

OCD is headquartered in Raritan, NJ, with manufacturing operations in New York, Florida, and Wales.

Source: The Carlyle Group

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines

Click here